Incyte to Present Oncology Data at ESMO 2026
Incyte says the data will include KRAS G12D and TGFβR2×PD-1 programs, informing ongoing registrational Phase 3 studies. An investor webcast is scheduled for Oct. 26.
Incyte says the data will include KRAS G12D and TGFβR2×PD-1 programs, informing ongoing registrational Phase 3 studies. An investor webcast is scheduled for Oct. 26.